ABT-510
Term · Oncology and biomedicine · MLC-T-ONC-000118
A substance being studied in the treatment of cancer. It is a type of angiogenesis inhibitor.
A synthetic peptide that mimics the anti-angiogenic activity of the endogenous protein thrombospondin-1 (TSP-1). ABT-510 inhibits the actions of several pro-angiogenic growth factors important to tumor neovascularization; these pro-angiogenic growth factors include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF)), hepatocyte growth factor (HGF), and interleukin 8 (IL-8).
| Identifier | MLC-T-ONC-000118 |
|---|---|
| Field | Oncology and biomedicine |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-000118",
"term": "ABT-510",
"field": "Oncology and biomedicine",
"definitions": [
"A substance being studied in the treatment of cancer. It is a type of angiogenesis inhibitor.",
"A synthetic peptide that mimics the anti-angiogenic activity of the endogenous protein thrombospondin-1 (TSP-1). ABT-510 inhibits the actions of several pro-angiogenic growth factors important to tumor neovascularization; these pro-angiogenic growth factors include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF)), hepatocyte growth factor (HGF), and interleukin 8 (IL-8)."
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/abt-510/"
}
Record 198 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.